CTOs on the Move

Optibrium

www.optibrium.com

 
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium`s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company`s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.optibrium.com
  • 125 Cambridge Park Drive Suite 301
    Cambridge, MA USA 02140
  • Phone: 978.234.4329

Executives

Name Title Contact Details
Ian Smith
 Chief Technology Officer Profile

Similar Companies

Affiliated Dermatologists, S.C.

Affiliated Dermatologists, S.C. is a Brookfield, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

febit

febit is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA SOLUTIONS

DNA SOLUTIONS is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PreciThera

PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.

Applied Genetic Technologies Corporation

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC`s lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC`s product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products